Navigation Links
Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Date:8/19/2007

Company on Target to File Supplemental New Drug Application in the Fourth

Quarter

FRAZER, Pa., Aug. 16 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced positive results from a 12-week, Phase 3 clinical trial of FENTORA(R) (fentanyl buccal tablet) [C-II] in patients with breakthrough pain associated with a broad range of chronic non-cancer pain conditions. The study achieved statistical significance on the primary endpoint. Results across the 12 weeks of treatment showed both statistically significant and clinically relevant outcomes for patients with breakthrough pain who were already receiving and who were tolerant to opioid therapy for their underlying persistent pain. FENTORA is approved only for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

"We are excited to complete our Phase 3 program with this third and final controlled study. These data show similar positive outcomes as those with FENTORA in treating breakthrough pain in opioid-tolerant patients with cancer, chronic neuropathic pain, and chronic low-back pain," said Dr. Lesley Russell, Executive Vice President, Worldwide Medical and Regulatory Operations. "We plan to submit these data to the Food and Drug Administration in the fourth quarter as part of our supplemental New Drug Application."

About the Study

The double-blind, placebo-controlled, variable dose Phase 3 trial included 148 patients. The primary endpoint was the Sum of Pain Intensity Differences from five to 60 minutes (SPID(60)) as assessed after 12 weeks of treatment. SPID(60) is a measure that assesses analgesic efficacy of a pain medication over the first 60 minutes after treatment. Patients treated with FENTORA showed a statistically significant improvement on the primary endpoint (p<0.0001) compared with placebo. FENTORA was general
'/>"/>

SOURCE Cephalon, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... Company,s Chief Financial Officer has resigned.  The Company has ... Officer who retired in December 2014, as full time ... permanent successor.     Andy Ashworth began ... ensure a smooth transition.  Andy was the Company,s CFO ...
(Date:7/29/2015)... 2015 Research and ... of the "Global Biosimilars Market, 2015 - ... The Global Biosimilars Market, 2015 - 2025, report ... biosimilars market. With the blockbuster biologics losing patent ... biosimilars are being viewed as viable substitutes to ...
(Date:7/29/2015)... July 29, 2015  Pfenex Inc. (NYSE MKT: PFNX) ... will be released on Thursday, August 13, 2015, before ... Pfenex management will host a conference call to discuss ... press release outlining the financial results and business update ... Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) and ...
(Date:7/29/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ... an optimized Erk inhibitor molecule for development, thus ... a new class of potential cancer therapies. ... target for therapeutic intervention in cancer. Recently approved ... for B-Raf and Mek inhibitors. Erk inhibitors may ...
Breaking Biology Technology:BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... on Form 20-F/A -- HONG KONG, Oct. 20 /PRNewswire-Asia-FirstCall/ -- ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
... Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") ... a new patent that provides broad protection on novel ... the "Zamore Design Rules."  European patent number 1 633 ... and Specificity of RNAi" was published today in the ...
... The Cold Triple Axis spectrometer, a new addition to ... a complementary tool to other neutron scattering instruments at ... uses "cold" neutrons from the HFIR cold source to ... slower than their "thermal" neutron counterparts, and thus perfect ...
Cached Biology Technology:China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 2China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 3China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 4China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 5China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 6China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 7China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 8Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent 2Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent 3ORNL's research reactor revamps veteran neutron scattering tool 2
(Date:7/20/2015)... 20, 2015  Acuity Market Intelligence,s latest research ... of Commerce and Privacy" forecasts that between 2014 ... will be downloaded to smart mobile devices by ... market is projected to generate more than $67.9 ... seven-year forecast period.    "Biometrics is ...
(Date:7/13/2015)... 13, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, ... 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND ... and secure method to make payments.  With this ... introduced with its groundbreaking voice-direct payment patent application, ...
(Date:7/9/2015)... , July 07, 2015 ... announced the addition of the "Biometrics for ... Forecasts 2015-2020" report to their offering. ... major contributor to this growth and the forecast ... billion in revenue for companies involved in delivering ...
Breaking Biology News(10 mins):Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... consortium has sequenced the genome of the woodland strawberry, ... advance online edition of the journal Nature Genetics ... breeding tastier, hardier varieties of the berry and other ... parts list," said the consortium,s leader Kevin Folta, an ...
... shock protein 90 (Hsp90) can create diverse heritable traits in ... portion of the yeast genome. The finding has led the ... in shaping the evolutionary history of the yeast genome, and ... several years, Whitehead Member Susan Lindquist has built the case ...
... The latest success of Martek Biosciences, a rising-star among ... a plain, brick building on the University of Maryland ... the university,s Maryland Technology Enterprise Institute (Mtech), the company ... business. On December 21, a Dutch firm ...
Cached Biology News:Georgia Tech team helps decode newly sequenced strawberry genome 2Georgia Tech team helps decode newly sequenced strawberry genome 3Heat shock protein drives yeast evolution 2Heat shock protein drives yeast evolution 3Heat shock protein drives yeast evolution 4Tech firm joins the 'billion dollar club' -- with university help 2Tech firm joins the 'billion dollar club' -- with university help 3
Recorder REC-111 single-channel, 1. Category: Chromatography Systems & Accessories, Systems....
For the quantitative determination of cyclic AMP (cAMP) concentrations in cell culture supernates, serum, plasma, saliva, urine and cell lysates....
... Cryoscope for molecular weight determinations for petroleum-based applications. Multiple solvents can be used, such as ... ... ... ...
... For the ultimate in utility and ... to meet the needs of the researcher. ... interior dimensions or as sheet material that ... enclosures. These isolators are autoclavable and non-cytotoxic ...
Biology Products: